The RNF19A antibody is a research tool designed to detect and study the RNF19A protein, a member of the RING (Really Interesting New Gene) finger family of E3 ubiquitin ligases. RNF19A, also known as Dorfin, plays a critical role in the ubiquitin-proteasome system (UPS), where it mediates substrate-specific protein ubiquitination, marking target proteins for degradation. This protein is implicated in cellular processes such as protein quality control, endoplasmic reticulum-associated degradation (ERAD), and the regulation of oxidative stress responses. Dysregulation of RNF19A has been linked to neurodegenerative diseases, particularly Parkinson’s disease, as it interacts with and ubiquitinates misfolded proteins, including pathogenic forms of α-synuclein and parkin, to prevent their toxic accumulation.
Antibodies against RNF19A are widely used in immunoblotting (Western blot), immunohistochemistry (IHC), and immunoprecipitation (IP) to investigate its expression, localization, and function in cellular and animal models. Researchers employ these antibodies to explore RNF19A’s role in disease mechanisms, its interaction partners, and its potential as a therapeutic target. Studies have shown that RNF19A overexpression may mitigate neurotoxicity by enhancing clearance of aggregated proteins, while its deficiency exacerbates proteinopathy in neurodegenerative conditions. However, the exact molecular pathways and context-dependent functions of RNF19A remain under active investigation, necessitating reliable antibodies for precise detection and functional analyses. Commercial RNF19A antibodies are typically validated for specificity and sensitivity across multiple applications to ensure reproducibility in experimental settings.